Prolight writes down capitalized development costs for MicroFlex and delays publication of the annual report
Today Prolight Diagnostics decided to write down the capitalized development costs regarding troponin testing on the analogue POC system MicroFlex with SEK 113 million. The impairment influences the result for 2023 but has no influence on the cash balance. The work with the annual report for 2023 is therefore delayed and the new publication date […]
Prolight announces positive accounting adjustments for the full year 2023
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announced today that the company’s 2023 year-end release contains an understated claim on the UK tax authority related to research and development. The revised estimate of Prolight’s claim is approximately SEK 5.6 million higher than previously reported. In the annual report for 2023, which will be […]
Prolight Diagnostics selects FlexMedical Solutions as CMO partner
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has appointed FlexMedical Solutions (FlexMedical) as its chosen Contract Manufacturing partner for the Psyros™ disposable cartridge. “The partnership is a major step in the development of the pilot manufacturing capabilities utilizing FlexMedical’s existing fully validated facilities and extensive IVD experience. One of the unique selling points […]
Emergers initiates equity research coverage of Prolight Diagnostics
Equity research firm Emergers has initiated coverage of Prolight Diagnostics. Excerpt from the equity research report: Having already achieved proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers in low concentrations by counting single molecules, Prolight’s first objective is now to pioneer the Point-of-Care (POC) troponin market. Next steps involve prototype development and […]
Prolight announces last day of trading in BTU and first day of trading in warrants of series TO6 and TO7
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Correction: Incorrectly applied MAR-label in previous press release. Prolight’s Board of Directors have decided to carry out a directed issue of units to underwriters in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Incorrectly […]
Prolight’s Board of Directors have decided to carry out a directed issue of units to underwriters in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight announces outcome in the rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight’s board and management increase their shareholdings
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Members […]
Prolight Diagnostics achieves ISO 13485 accreditation
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, today announces that their subsidiary Psyros Diagnostics has gained accreditation to the industry standard ISO 13485, which sets out the requirements for a quality management system (QMS) specific to the medical devices industry. “The accreditation shows that our quality processes meet global quality requirements which is […]